Cited 0 times in
신장이식 前後에 측정한 각종 C형 간염바이러스 표식자 양성의 의미 -제3세대 ELISA 항체검사와 PCR법에 의한 RNA 검사를 중심으로 -
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유선 | - |
dc.contributor.author | 김현숙 | - |
dc.date.accessioned | 2020-07-03T17:46:34Z | - |
dc.date.available | 2020-07-03T17:46:34Z | - |
dc.date.issued | 1997 | - |
dc.identifier.issn | 1298-1711 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/177818 | - |
dc.description.abstract | Currently accurate test for identification of HCV infection is not yet developed. We examined 1) the relationship between the result of anti-HCV by 3rd generation ELISA (ELISA/3) and of HCV-RNA by PCR from pre-transplant stored serum in 89 living donor renal transplant recipients and 2) the correlation between the result of each or combined tests and the development of post-transplant liver dysfunction (LDF). LDF was defined as the increment of serum transaminase over 100 1.U./ml in two consecutive tests. Patients with climically or biopsy proven LDF by cyclosporine were excluded. Pre-transplant HCV infection rate sed by ELISA/3 and PCR was 20.2 and 29.2% respectively. Patients with PCR (+) developed LDF frequently comparesd with negative partners (50 vs. 27%, p=0.0367). Significant disparity between ELISA/3 and PCR was present. In 71 ELISA/3 (-) patients, 16(22.5%) were positive for PCR. However 8 (44.4%) were negative for PCR in 18 ELISA/3 (+) patients. ELISA/3 (+) or PCR (+) patients developed LDF frequently rather than ELISA/3 (-)/PCR(- ) ones(50.0 vs. 23.6%, p=0.0106). We could explain these data with S possibilities, 1) end-stage renal failure patients had a blunt antibody production, 2) serum sample may be collected during the window period for antibody formation, 3) even ELISA/3 could not detect fine molecular response during the early HCV infection(false negative), 4) significant false positive or serum contamination in PCR test, and finally 5) self-clearing of HCV antigen may be present in the body. In conclusion, HCV detection by PCR method and antibody test by ELISA/3 must be complementary for the accurate evaluation of HCV infection during the recipient evaluation and posttransplantation follow-up period. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | Journal of the Korean Society for Transplantation | - |
dc.publisher | Journal of the Korean Society for Transplantation | - |
dc.relation.isPartOf | Journal of the Korean Society for Transplantation | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 신장이식 前後에 측정한 각종 C형 간염바이러스 표식자 양성의 의미 -제3세대 ELISA 항체검사와 PCR법에 의한 RNA 검사를 중심으로 - | - |
dc.title.alternative | Combined Interpretation of Pretransplant Anti - hepatitis C Virus ( HCV ) Antibody by 3rd Generation ELISA and HCV - RNA by Polymerase Chain Reaction ( PCR ) for the Prediction of Posttransplant Liver Dysfunction | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | 김유선 | - |
dc.contributor.googleauthor | 김명수 | - |
dc.contributor.googleauthor | 이준호 | - |
dc.contributor.googleauthor | 김현숙 | - |
dc.contributor.googleauthor | 김순일 | - |
dc.contributor.googleauthor | 문장일 | - |
dc.contributor.googleauthor | 오소향 | - |
dc.contributor.googleauthor | 이은미 | - |
dc.contributor.googleauthor | 이호영 | - |
dc.contributor.googleauthor | 박기일 | - |
dc.contributor.localId | A00785 | - |
dc.contributor.localId | A01117 | - |
dc.relation.journalcode | J01858 | - |
dc.identifier.eissn | 2508-2604 | - |
dc.identifier.url | http://kiss.kstudy.com/thesis/thesis-view.asp?key=2503003 | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | 김유선 | - |
dc.contributor.affiliatedAuthor | 김현숙 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 73 | - |
dc.citation.endPage | 80 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Society for Transplantation, Vol.11(1) : 73-80, 1997 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.